PE110398A1 - Productos intermedios y proceso para preparar olanzapina - Google Patents

Productos intermedios y proceso para preparar olanzapina

Info

Publication number
PE110398A1
PE110398A1 PE1997000855A PE00085597A PE110398A1 PE 110398 A1 PE110398 A1 PE 110398A1 PE 1997000855 A PE1997000855 A PE 1997000855A PE 00085597 A PE00085597 A PE 00085597A PE 110398 A1 PE110398 A1 PE 110398A1
Authority
PE
Peru
Prior art keywords
olanzapine
polymorph
methyl
refers
intermediate products
Prior art date
Application number
PE1997000855A
Other languages
English (en)
Inventor
Arthur Bunnell Charles
Dean Larsen Samuel
Richard Nichols John
Marie Reutzel Susan
Alan Stephenson Gregory
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832120&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE110398(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE110398A1 publication Critical patent/PE110398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE AL PROCEDIMIENTO DE PREPARACION DEL 2-METIL-4-(4-METIL-1-PIPERAZINIL)-1OH-TIENO[2,3-b][1,5]BENZODIAZEPINA (OLANZAPINA) DE FORMA II, QUE COMPRENDE: DESHIDRATAR UN DIHIDRATO DE OLANZAPINA EN UN VACUOHORNO A UNA TEMPERATURA ENTRE 40�C a 70�C. ESTE PROCESO PERMITE LA OBTENCION DE LA FORMA II (FORMA ANHIDRA MAS ESTABLE DE OLANZAPINA) SUSTANCIALMENTE PURA, QUE TENDRA APROXIMADAMENTE MENOS DE 0,5% DE IMPUREZAS QUIMICAS O SOLVENTES RESIDUALES INDESABLES. TAMBIEN SE REFIERE A LOS POLIMORFOS "B" Y "E" DEL DIHIDRATO DE OLANZAPINA; EN DONDE EL POLIMORFO "B" SE CARACTERIZA POR EL SIGUIENTE PATRON DE DIFRACCION DE RAYOS X: 9,9045 6,9985 6,763 6,4079 6,1548 6,0611 5,8933 5,6987 5,4395 5,1983 5,0843 4,9478 4,7941 4,696 4,5272 4,4351 4,3474 4,2657 4,1954 4,0555 3,9903 3,9244 3,8561 3,8137 3,7671 3,6989 3,6527 3,5665 3,4879 3,3911 3,3289 3,2316 3,1982 3,1393 3,0824 2,9899 2,9484 2,9081 2,8551 2,8324 2,751 2,7323 2,6787 2,6424 2,5937; Y EL POLIMORFO "E" SE CARACTERIZA POR EL SIGUIENTE PATRON DE DIFRACCION DE RAYOS X: 9,871 9,5514 6,9575 6,141 6,0644 5,9896 5,8774 4,7721 4,6673 4,5171 4,4193 4,354 4,2539 4,2369 4,0537 4,0129 3,8555 3,7974 3,6846 3,5541 3,4844 3,474 3,4637 3,3771 3,1245 2,9403. LA OLANZAPINA ES USADA EN EL TRATAMIENTO ANTIPSICOTICO
PE1997000855A 1996-09-23 1997-09-23 Productos intermedios y proceso para preparar olanzapina PE110398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2648796P 1996-09-23 1996-09-23

Publications (1)

Publication Number Publication Date
PE110398A1 true PE110398A1 (es) 1999-01-14

Family

ID=21832120

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000855A PE110398A1 (es) 1996-09-23 1997-09-23 Productos intermedios y proceso para preparar olanzapina

Country Status (36)

Country Link
US (1) US6020487A (es)
EP (1) EP0831098B1 (es)
JP (2) JP2001500877A (es)
KR (1) KR100560015B1 (es)
CN (1) CN1122036C (es)
AR (1) AR013838A1 (es)
AT (1) ATE209208T1 (es)
AU (1) AU719441B2 (es)
BR (1) BR9712100A (es)
CA (1) CA2265712C (es)
CO (1) CO4910140A1 (es)
CZ (1) CZ299248B6 (es)
DE (1) DE69708428T2 (es)
DK (1) DK0831098T3 (es)
EA (1) EA001642B1 (es)
EG (1) EG23861A (es)
ES (1) ES2166051T3 (es)
HK (1) HK1009807A1 (es)
HU (1) HU226484B1 (es)
ID (1) ID27275A (es)
IL (1) IL128962A (es)
IN (1) IN187156B (es)
MY (1) MY125565A (es)
NO (1) NO323980B1 (es)
NZ (1) NZ334448A (es)
PE (1) PE110398A1 (es)
PL (3) PL196069B1 (es)
PT (1) PT831098E (es)
RS (1) RS49598B (es)
SI (1) SI0831098T1 (es)
SV (1) SV1997000081A (es)
TR (1) TR199900640T2 (es)
TW (1) TW470746B (es)
UA (1) UA59371C2 (es)
WO (1) WO1998012199A1 (es)
ZA (1) ZA978515B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2420987A1 (en) * 2000-08-31 2002-03-07 Dr. Reddy's Laboratories Ltd. Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
US6740753B2 (en) * 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
JP4530664B2 (ja) 2001-12-24 2010-08-25 サン・ファーマシューティカル・インダストリーズ・リミテッド ２−メチル−４−（４−メチル−１−ピペラジニル）−１０Ｈ−チエノ［２，３−ｂ］［１，５］ベンゾジアゼピンの結晶形Ｉ、この結晶形Ｉの製造方法、及び医薬組成物
WO2003091260A1 (en) * 2002-04-23 2003-11-06 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
AU2003237305A1 (en) 2002-05-31 2003-12-19 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
AU2003300324A1 (en) 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
ATE397611T1 (de) * 2003-12-22 2008-06-15 Teva Pharma Verfahren zur herstellung von olanzapin
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
US20070072845A1 (en) * 2004-02-19 2007-03-29 Davuluri Rammohan Rao Process for the preparation of olanzapine form 1 useful as antipsychotic drug
DE05783995T1 (de) * 2004-07-14 2007-10-11 Shasun Chemicals and Drugs Ltd., Chennai Verbessertes verfahren zur herstellung von form i aus olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
ES2303462B1 (es) 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
EP2486913A1 (en) 2011-02-14 2012-08-15 Labtec GmbH Rapidly disintegrating oral film formulation for Olanzapin
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302716A (en) * 1986-01-16 1994-04-12 Schering Corporation Fused benzazepines
CA2002596A1 (en) * 1988-11-14 1990-05-14 Thomas M. Eckrich Hydrates of b-lactam antibiotic
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
NO305125B1 (no) * 1992-05-29 1999-04-06 Lilly Industries Ltd Farmas°ytiske forbindelser
US5550231A (en) * 1993-06-15 1996-08-27 Eli Lilly And Company Loracarbef hydrochloride C1-C3 alcohol solvates and uses thereof
US5602124A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
US5631250A (en) * 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
NZ334346A (en) * 1996-09-23 2000-05-26 Lilly Co Eli Olanzapine dihydrate D comprising 2-methyl-4-(4-methyl-1-piperazinyl)-1OH-thieno[2,3-b][1,5]benzodiazepine and a formulation for use in treating central nervous system disorders

Also Published As

Publication number Publication date
TR199900640T2 (xx) 1999-06-21
ZA978515B (en) 1999-03-23
KR20000048520A (ko) 2000-07-25
HU226484B1 (en) 2009-03-02
EP0831098B1 (en) 2001-11-21
IN187156B (es) 2002-02-16
SV1997000081A (es) 1999-01-14
RS49598B (sr) 2007-06-04
PL332482A1 (en) 1999-09-13
YU15599A (sh) 2001-12-26
HK1009807A1 (en) 1999-06-11
IL128962A0 (en) 2000-02-17
UA59371C2 (uk) 2003-09-15
CZ299248B6 (cs) 2008-05-28
HUP0000066A3 (en) 2000-11-28
NO991382D0 (no) 1999-03-22
DK0831098T3 (da) 2002-05-21
EA199900326A1 (ru) 1999-08-26
KR100560015B1 (ko) 2006-03-15
NO323980B1 (no) 2007-07-30
HUP0000066A2 (hu) 2000-06-28
SI0831098T1 (en) 2002-04-30
BR9712100A (pt) 1999-08-31
CN1234802A (zh) 1999-11-10
PL196069B1 (pl) 2007-12-31
JP2009242407A (ja) 2009-10-22
JP2001500877A (ja) 2001-01-23
EA001642B1 (ru) 2001-06-25
DE69708428D1 (de) 2002-01-03
TW470746B (en) 2002-01-01
AR013838A1 (es) 2001-01-31
ID27275A (id) 2001-03-22
DE69708428T2 (de) 2002-07-04
CZ99099A3 (cs) 1999-11-17
EP0831098A3 (en) 1998-04-29
AU719441B2 (en) 2000-05-11
CA2265712A1 (en) 1998-03-26
CO4910140A1 (es) 2000-04-24
EG23861A (en) 2007-11-18
PL194565B1 (pl) 2007-06-29
CA2265712C (en) 2006-10-31
US6020487A (en) 2000-02-01
AU4484197A (en) 1998-04-14
IL128962A (en) 2003-01-12
PT831098E (pt) 2002-04-29
EP0831098A2 (en) 1998-03-25
NZ334448A (en) 2000-08-25
WO1998012199A1 (en) 1998-03-26
PL196068B1 (pl) 2007-12-31
MY125565A (en) 2006-08-30
ATE209208T1 (de) 2001-12-15
CN1122036C (zh) 2003-09-24
NO991382L (no) 1999-03-22
ES2166051T3 (es) 2002-04-01

Similar Documents

Publication Publication Date Title
PE110398A1 (es) Productos intermedios y proceso para preparar olanzapina
ES2112971T3 (es) Procedimiento para el tratamiento de fibras para la fabricacion de papel de seda.
DK0751129T3 (da) Substituerede dihydrodibenz/b,f/azepiner, fremgangsmåde til fremstilling deraf, deres anvendelse i behandlingen af nogle li
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GT199900019A (es) Formulas farmaceuticamente estables de solucion de oxaliplatino.
YU44900A (sh) Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
ES2037755T3 (es) Procedimiento para la fabricacion de un material de hidroxilapatita.
ES2106700T3 (es) Procedimiento para la preparacion de derivados de la 4a,5,9,10,11,12-hexahidro-6h-benzofuro(3a,3,2-ef)(2)benzacepinas.
NO913689L (no) Fremgangsmaate ved fremstilling av silisiumbarrer med hoey renhet.
NO160579C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive omega-(1,4,5-trifenylimidazol-2-yloksy)-alkansyrer og disses derivater.
DE69017789T2 (de) 1,2,3,4-Tetrahydro-9-Akridinaminderivate.
NO178968C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidin-karboksamidderivater
ES2091324T3 (es) Proceso para la preparacion de aspartama a partir de una dicetopiperazina y nuevos compuestos intermedios y derivados para dicho proceso.
RO77280A (ro) Procedeu pentru prepararea unor izocianati aromatici de inalta puritate
ES2071303T3 (es) Compuestos homologados de vitamina d2 y los derivados hidroxilados en 1alfa correspondientes.
PT91414A (pt) Processo para a preparacao de 2-fenil-1,2-benzisosselenazol-3(2h)-ona(ebseleno) sob uma forma muito pura
PE38197A1 (es) Procedimiento para preparar solvatos de 2-metil-tieno-benzodiacepina (olanzapina)
NO176357C (no) Analogifremgangsmåte for fremstilling av 4,5,7,8-tetrahydro-6H-tiazolo [5,4-dÅ- azepiner
FI92320C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten bisfenyylialkyylipiperatsiinijohdannaisten valmistamiseksi
NO174423C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive tieno(3,2-b)pyraner
ES2092785T3 (es) Nuevo procedimiento de preparacion de compuestos esteroides de 20-ceto-21alfa-hidroxi y productos intermedios.
ES2053590T3 (es) 3-fenil-7h-tiazolo(3,2-b)(1,2,4)triazin-7-onas sustituidas, procedimiento para su preparacion, medicamentos que las contienen y su empleo, asi como algunos productos intermedios formados durante la preparacion de los compuestos mencionados.
CS274578B2 (en) Method of substituted 5-halogenthienoisothiazole-3 (2h)-on-1,1-dioxides production
FI910159A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 9a-hydroxi-3-oxo-4,24(25)-stigmastadien-26 -syraderivat.
JPS53123669A (en) Wafer holding method

Legal Events

Date Code Title Description
FG Grant, registration